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Ingiridur Skirnisdottir1*, Kathrine Bjersand1, Helena Åkerud1 and Tomas Seidal2Abstract
Background: Clear cell carcinomas are aggressive tumors with a distinct biologic behaviour. In a genome-wide
screening for genes involved in chemo-resistance, NAPA was over-expressed in cisplatin-resistant cells. The NAPA
(protein) Napsin A was described to promote resistance to cisplatin by degradation of the tumor suppressor p53.
Methods: Totally 131 patients were included in this study all in FIGO-stages I-II; 16 were clear cell tumors which
were compared with 40 Type I tumors and 75 type II tumors according to the markers Napsin A, p21, p53 and p27
and some clinical features. For detection of the markers tissue microarrays and immunohistochemistry were used.
Results: Positivity for Napsin A was detected in 12 (80%) out of the 15 clear cell tumors available for analysis
compared with 3 (4%) out of the Type I and II tumors in one group (p < 0.001). Differences in p21 status, p53 status,
and p21 + p53- status were striking when clear cell tumors were compared with Type I, Type II, and Type I and II
tumors in one group, respectively. The p21 + p53-status was associated to positive staining of Napsin A (p = 0.0015)
and clear cell morphology (p = 0.0003). In two separate multivariate logistic regression analyses with Napsin A as
endpoint both clear cell carcinoma with OR = 153 (95% C.I. 21–1107); (p < 001) and p21 + p53- status with OR = 5.36
(95% C.I. 1.6-17.5); (p = 0.005) were independent predictive factors. ROC curves showed that AUC for Napsin A alone
was 0.882, for p21 + p53- it was 0.720 and for p21 + p53-Napsin A + AUC was 0.795. Patients with clear cell tumors
had lower (p = 0.013) BMI than Type I patients and were younger (p = 0.046) at diagnosis than Type II patients. Clear
cell tumors had a higher frequency (p = 0.039) of capsule rupture at surgery than Type I and II tumors.
Conclusions: Positivity of Napsin A in an epithelial ovarian tumor might strengthen the morphological diagnosis of
clear cell ovarian carcinoma in the process of differential diagnosis between clear cell ovarian tumors and other
histological subtypes.
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Epithelial ovarian cancer (EOC) is the main cause of
death among women with gynecologic malignancies [1].
At present, post-surgical therapy is mainly dependent
upon tumor stage and grade rather than histological
subtype [2]. On the basis of a series of morphologic and
molecular genetic studies various types of ovarian cancer
can be classified into two groups designated type I and
type II [3,4]. Clear cell carcinoma (CCC), which consti-
tutes 5-6% of ovarian malignancies exhibit morphologic,
molecular, and clinical features that do not entirely
resemble either Type I or Type II tumors and unlike,* Correspondence: ingiridur.skirnisdottir@ kbh.uu.se
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distribution, and reproduction in any mediumother Type I tumors, clear cell carcinoma CCC is high
grade at presentation [4,5].
Consequently, most authorities in the field recom-
mend that ovarian clear cell carcinomas should be
automatically classified as grade 3 [2,3]. This is also in
agreement with recent findings from Zannoni et al. [4],
where they show that clear cell ovarian carcinoma
should be studied separately, but still in comparison with
the groups of Type I and Type II tumors. In a study
from Chan et al. [6] it was concluded, that women with
clear cell ovarian carcinoma are likely to be younger at
diagnosis. Clear cell carcinoma usually presents as a
pelvic mass with higher frequency of capsule rupture
than other subtypes and it is known since before that
this subtype is associated with endometriosis [7,8]. Clearntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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trial, found to present mostly as FIGO-stages I/II at
diagnosis [9].
Many studies have found that clear cell carcinoma has
a distinct aggressive biologic behaviour with poor re-
sponse to platinum-based therapy compared to other
subtypes of epithelial ovarian cancer [6]. Ovarian clear
cell carcinoma may be more closely related to other
clear cell tumors than other subtypes of ovarian cancer
[10]. Cisplatin act mainly by inducing apoptosis in
cancer cells and it has been shown in mouse studies as
well as in the clinics that intact wild-type p53 is required
for efficient execution of apoptosis. In clear cell car-
cinoma wild-type p53 is mostly present and mutations
are uncommon [10,11].
Recently, it was shown in genome-wide screening for
genes involved in chemo-resistance, that NAPA consist-
ently was over-expressed in cisplatin-resistant cells [12].
The gene NAPA has been detected on chromosome 19q
13.33 and the corresponding protein Napsin A is an
aspartic peptidase [13]. It was found to represent an anti-
apoptotic protein that promotes resistance to cisplatin by
degradation of the tumor suppressor p53, which is regu-
lator of the cell cycle and co-works with cyclin kinase
inhibitors as p21 and p27 [14-16]. The p21 gene is a
primary mediator of p53-induced cell cycle arrest [17].
Napsin A is known to be present in primary lung adeno-
carcinomas as well as renal cell carcinoma (papillary and
clear cell subtypes). As Napsin A is usually absent in the
neoplastic cells in squamous carcinoma (pulmonary and
non-pulmonary) it has been used as a diagnostic tool to
distinguish between these two types of tumors [18].
Methods
Study population
A total of 140 consecutive patients with FIGO-stage I-II
epithelial ovarian cancer, who underwent primary
surgery and post-surgical chemotherapy in the Uppsala-
Örebro Medical Region during at the 5-year period from
January 1, 2000 to December 31, 2004, were entered into
this study. All samples were collected with the patient’s
informed consent and were in compliance with the
Helsinki Declaration [19] and used in accordance with
the Swedish Biobank Legislation and Ethical Review Act
(approval by Uppsala Ethical Review Board, decision ref.
UPS-03-477).
In total, 131 patients were included in this study and
there were 131 available tumors for analysis of p53 and
p27, 129 tumors for analysis of p21, and 124 tumors
available for analysis of Napsin A (lower numbers be-
cause of technical issues in the staining process).
The primary surgery was performed at nine different
surgical gynecological departments and the staging
procedure was done at the time of primary surgery.Modified surgical staging according to the EORTC
surgical staging categories in early ovarian cancer [20]
was undertaken in 34 (26%) out of the 131 cases, and in
the remaining 77 (74%) patients surgical staging was
regarded as minimal or inadequate according to the
same guidelines. All patients had chemotherapy 4–6 weeks
after primary surgery. In the total series 105 out of the
131 (80%) of patients received paclitaxel 175 mg/m2 and
carboplatin (AUC= 5) at 3-week intervals usually in four
courses. The remaining 26 patients were treated with
single-drug carboplatin in 4–6 courses. No patients were
lost from clinical follow-up and the mean follow-up time
was 65 months (range 5–110 months). Survival was
defined as date of confirmed histological diagnosis after
primary surgery to date of recurrence, death or last visit.
Ovarian tissue microarray and Immunohistochemistry
The specimens were obtained from the paraffin blocks
containing the embedded tissue removed from the
tumor at primary surgery and after staining with hemo-
toxylin and eosin they were classified and graded by a
single pathologist. The tissue microarrays were con-
structed as described previously [21]. In brief, tumor
tissues were embedded in paraffin and 5 μm sections
stained with hematoxylin-eosin were obtained to select
representative areas for biopsies. Core tissue biopsy
specimens (diameter 0.6 mm) were taken from these
areas of individual donor paraffin blocks and precisely
arrayed into a new recipient paraffin block with a
custom-built instrument. Tissue core specimens from
131 ovarian carcinomas were arranged in three recipient
paraffin blocks. Two core biopsies were obtained from
each specimen. The presence of tumor tissue on the
arrayed samples was verified by hematoxylin-eosin-
stained section by a pathologist.
Five μm thick sections were cut from each multi tissue
block and were put on coated slides and dried overnight at
37°C. The sections were pre-treated by heath-induced
epitope retrieval in target- retrieval solution (Dako), pH= 6
or EDTA buffer pH = 9, for 7 + 7 minutes in microwave
oven (99°C). Blocking with peroxidase was performed for
5 minutes. The slides were counterstained with hema-
toxylin for 2 minutes. The following monoclonal primary
antibodies were used: NCL-L Napsin A (dilution 1:400,
mouse monoclonal antibody, Novocastra, Newcastle,
UK), DO-7, directed against p53 protein (dilution
1:1000; Dako, Glostrup, Denmark), p21 protein (dilu-
tion 1:50; Dako, Glostrup, Denmark) and NCL-p27
(dilution 1:40; Vision Biosystems Novocastra, Newcastle,
UK). The immunostainings were performed in an Auto-
stainer automated machine (Dako) using REAL Envision
detection system (Dako). The work of tissue-microarray
construction was undertaken at the Department of
Pathology, the University Hospital MAS Malmö, Sweden,
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interpretation were performed at the Department of
Pathology, Halmstad Medical Central Hospital, Sweden.
Interpretation
The immunohistochemical (IHC) stains were interpreted
by two of the authors (IS and TS). At the time for eva-
luation, no information was available on the specific
diagnosis and prognosis for the individual cases. A semi-
quantitative analysis [22] was used and the stainings
were graded as negative, +, ++, and +++ for Napsin A,
p21, p53 and p27. All markers were dichotomized into
negative and positive (+, ++, +++) cases [23].
The staining for Napsin A in the tumor cells was con-
sidered to be positive (Figure 1) if there was a distinct
granular staining in the cytoplasm and no background
staining could be detected. In Additional files IHC
pictures from sections of ovarian clear cell carcinoma
are shown. Thus, an IHC picture in an Additional file 1
was demonstrating weak (+) Napsin A positivity, an IHC
picture in an Additional file 2 was demonstrating mode-
rate (++) Napsin A positivity and an IHC picture in an
Additional file 3 was demonstrating strong (+++) Napsin
A positivity. In an Additional file 4 Napsin A negativity
in a section of ovarian clear cell carcinoma was
demonstrated.
The staining for p21 and p53 was considered to be
positive when there was a strong and granular staining
of the nuclei of the majority of tumor cells. Finally, the
staining for p27 was considered to be positive when
strong and granular staining of the nuclei and cytoplasm
of the tumor cells was found.Figure 1 Section of ovarian clear cell carcinoma demonstrating stron
the tumor cells.Statistical analysis
The Pearson’s Chi-square test was used for testing pro-
portional differences in univariate analyses. The survival
curves were generated by using the Kaplan-Meier tech-
nique and differences between these curves were tested
by the log-rank test. All tests were two-sided and the
level of statistical significance was p < 0.05. By means of
Receiver operating characteristic (ROC) curves Area
under the curve (AUC) was determined for Napsin A,
p21 + p53- and p21 + p53-Napsin A+. For multivariate
analyses the logistic regression model was used with
positivity of Napsin A as the end point. The Statistica11.0
(StatSoft™) statistical package for personal computers was
used for the analyses.
Results
Background characteristics
Patients’ characteristics, e.g. age, performance status
(according to WHO), FIGO-stage, histology, and FIGO-
grade are demonstrated in Table 1. The study population
included 40 type I tumors (30.5%), 75 type II tumors
(57.3%), and 16 clear cell carcinomas (12.2%) shown in
Table 2. Primary cure was achieved in all 131 patients
(100%). The total number of recurrences in the complete
series was 34 out of 131 (26%), and 22 of these patients
(67.0%) died due to their disease. Five patients (15%)
with recurrent disease died due to intercurrent dis-
ease and 7 (18%) patients were still alive at the last
follow-up.
In the complete series, recurrent disease was significantly
associated with FIGO sub-stages (p = 0.0005), FIGO-grade
(p = 0.030), adequate surgical staging (p = 0.033) andg (+++) Napsin A positivity as granular cytoplasmic staining in
Table 1 Patients’characteristics (N=131)
Age (median) 59.0 (Range 25-84)














Clear cell* 16 (12.2)
Anaplastic 2 (1.5)
FIGO-grade
Grade 1 31 (23.7)
Grade 2 45 (34.4)
Grade 3* 55 (41.9)
Clear cell* (all clear cell tumors were graded as grade 3 tumors).
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capsule rupture at surgery and ascites at primary
surgery were not associated with recurrent disease. In
the complete series the 5-year disease-free survival
rate was 68%, the disease-specific survival rate 76%,
and the overall survival rate 71%.
Immunohistochemistry
Staining of Napsin A was confined to the cytoplasm of the
tumor cells. Positivity for Napsin A was observed in 16Table 2 Type I tumors and type II tumors according to
combination of histological subtype and FIGO-grade
Types of ovarian tumors (after histopathology
and tumor grade)
N (%)
Type I tumors 40 (30.5)
Low-grade (G1) serous 14
Mucinous (G1+G2+G3) 20
Low-grade (G1) endometrioid 6
Type II tumors 75 (57.3)
High-grade (G2+G3) serous 37
High-grade (G2+G3) endometrioid 36
Anaplastic 2
Clear cell tumors 16 (12.2)
Clear cell tumors were all graded as G3 tumors.(13%) out of the 124 tumors available for interpretation of
this marker. In 15 out of the 16 clear cell tumors results
from IHC for Napsin A were available. Positivity for
Napsin A was detected in 12 (80%) out of the 15 clear cell
tumors (Table 3). The difference was highly significant
compared to Type I tumors, type II tumors and Type I
and II tumors in one group, respectively. Status of Napsin
A was associated to p21p53 status. Thus, concomitant
positivity for p21 and negativity for p53 staining was
detected in 10 out of the 15 tumors with positivity for
Napsin A (67%) compared with 28 out of 107 (26%)
tumors with negativity for Napsin A (p = 0.0015). The
Napsin A status was not related to FIGO-stage or recur-
rent disease. In survival analysis there was no differences
in 5 year disease-free survival after the Napsin A status
(Log-rank = 28.017; p = 0.822).
Staining of p53, p21 and p27
In previous studies [24,25] including the total series of
patients (N = 131), results from IHC for p21, p27 and
p53 have been presented. Status of protein expression in
tumors of p21 (N = 129) and p27 and p53 (N = 131) was
analysed according to clinico-pathological features (age,
histopathological subtype, FIGO-grade, FIGO-stages,
and recurrent disease) and survival. The distribution of
four subgroups was analysed based on the p53 status,
p21 status and p27 status of tumors according to the
same variables. Furthermore, in a previous study [25]
the complete series of 129 patients was split into two
subgroups according to concomitant p21- and p53+ of
the tumors compared with other in one group (p21 +
p53+, p21 + p53-, p21-p53-) and the distribution of the
subgroups were analysed according to the same features
as before.
Concomitant staining of p21 and p53
In the present study, the p21 p53 status was split into
two subgroups according to concomitant p21 + p53- in
one group (N = 39) compared with other combinations
(p21 + p53+, p21-p53+, p21-p53-) in a second group
(N = 90) (Table 3). Among clear cell tumors 11 (69%)
out of the 16 carcinomas were belonging to the sub-
group of concomitant positivity for p21 and negativity
for p53 compared with the remaining five (31%) clear
tumors in the study where other combinations of p21
p53 status were presented.
This was different from Type I tumors (p = 0.0003),
type II tumors (p = 0.002) and Type I and II tumors in
one group (p = 0.0003) (Table 3). Furthermore, only one
(5%) out of the 19 mucinous tumors had concomitant
staining for p21+ p53- (p = 0.0007) (data not shown).
Status of concomitant p21+ and p53- in tumors com-
pared with other combinations (p21 + p53+, p21-p53+,
p21-p53-) in one group was not associated to FIGO-
Table 3 Status of protein expression in tumors of the Napsin A, p21, p53, p21 + p53-/other in one group and p27
versus clear cell tumors compared to Type I tumors, Type II tumors and Type I and II tumors
N (%) N (%) N (%) N (%) N (%) N (%)
16 (29) 40 (61) 16 (18) 75 (82) 16 (12) 115 (88)
Clear cell Type I Clear cell Type II Clear cell Other (Type I+II)
Tumors Tumors Tumors Tumors Tumors Tumors
Positivity
NapsinA+ 12 (80) 1 (3) 12 (80) 3 (4) 12 (80) 4 (4)
NapsinA- 3 (20) 34 (97) 3 (20) 71 (96) 3 (20) 105 (96)
p = 0.0000 p = 0.0000 p = 0.0000 (chi-2)
p21+ 11 (69) 11 (28) 11 (69) 24 (32) 11 (69) 35 (31)
p21- 5 (31) 28 (72) 5 (31) 50 (68) 5 (31) 78 (69)
p = 0.005 p = 0.007 p = 0.003 (chi-2)
p53+ 0 (00) 11 (28) 0 (00) 22 (29) 0 (00) 33 (29)
p53- 16 (100) 29 (72) 16 (100) 53 (71) 16 (100) 82 (71)
p = 0.019 p = 0.012 p = 0.013 (chi-2)
p21+p53- 11 (69) 7 (18) 11 (69) 21 (28) 11 (69) 28 (25)
Other# 5 (31) 32 (82) 5 (31) 53 (72) 5 (31) 85 (75)
p = 0.0003 p = 0.002 p = 0.0003 (chi-2)
p27+ 11 (69) 12 (30) 11 (69) 52 (69) 11 (69) 64 (56)
p27- 5 (31) 28 (70) 5 (31) 23 (31) 5 (31) 51 (44)
p = 0.007 p = 0.963 p = 0.321 (chi-2)
Other# (p21+p53+, p21-p53+, p21-p53-)
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vival analysis there were no differences in 5 year survival
between the group of patients with p21 + p53- in tumors
compared with the group of patients, whose tumors had
other combinations of p21p53 status (Log-rank = 9.552;
p = 0.341).
Clear cell versus Type I ovarian carcinoma
The mean age of patients with clear cell carcinomas
(54.7 years) did not significantly differ from that in Type
I group (57.2 years) (Table 4). However, the group of
patients with clear cell carcinomas had significantly
(p = 0.013) lower BMI compared to the Type I group.
No difference according to the FIGO sub-stages or
recurrent disease between the two groups of patients
could be detected. However, capsule rupture occurred
more frequently (p = 0.039) in clear cell tumors compared
with Type I tumors. There was no difference in disease –
free survival between the group of patients with clear cell
tumors compared with the group of patients with Type I
tumors (Log-rank = 29.690; p = 0.623).
Differences in Napsin A status were highly significant
between the two groups (Table 3). Thus, 12 out of the
15 (80%) clear cell carcinomas stained positively for
Napsin A compared with only one out of the 35 (3%)
Type I tumors. Differences in the p21 status, p53 status,p21 + p53- versus other combinations in one group and
p27 status were also striking between the two groups
(p = 0.005), (p = 0.019), (p = 0.003) and (p = 0.007), res-
pectively. In summary clear cell carcinomas usually
stained positively for Napsin A, p21 and p27, but
conversely p53 was absent alone or in combination
with positive staining for p21.Clear cell versus Type II ovarian carcinoma
The patients with clear cell carcinomas was significantly
(54.7 years) younger than patients in the Type II group
(60.2 years) (p = 0.046). However, no differences were
found according to BMI divided in two groups, FIGO
sub-stages or recurrent disease (Table 4) between the two
groups of patients, whereas capsular rupture occurred
more frequently (p = 0.027) in clear cell tumors compared
with Type II tumors. There was no difference in disease –
free survival between the group of patients with clear cell
tumors compared with the group of patients with Type II
tumors (Log-rank = 29.690; p = 0.623).
Likewise, the differences in immunohistochemical pro-
file for all markers, with exception of p27 were striking
between the two groups of clear cell and Type II tumors
(Table 3) in the same manner as before in comparison
with Type I tumors.
Table 4 Clinical features of clear cell tumors compared to Type I tumors, Type II tumors and Type I and II tumors in
one group
N (%) N (%) N (%) N (%) N (%) N (%)
16 (29) 40 (61) 16 (18) 75 (82) 16 (12) 115 (88)
Clear cell Type I Clear cell Type II Clear cell Other (Type I+II)
Tumors Tumors Tumors Tumors Tumors Tumors
Age 54.7 57.2 54.7 60.2 54.7 59.1
p = 0.388 p = 0.046 p = 0.100 (t-test)
BMI ≤ 25 11 (73) 11 (36) 11 (73) 44 (61) 11 (73) 58 (52)
BMI > 25 4 (27) 25 (64) 4 (27) 28 (39) 4 (27) 53 (48)
p = 0.013 p = 0.372 p = 0.123 (chi-2)
STAGE
IA-B 3 (19) 20 (50) 3 (19) 22 (29) 3 (19) 42 (19)
IC 10 (62) 16 (40) 10 (62) 40 (54) 10 (62) 56 (49)
II 3 (19) 4 (10) 3 (19) 13 (17) 3 (19) 17 (15)
p = 0.097 p = 0.669 p = 0.341 (chi-2)
Capsule
Rupture*
Yes 10 (63) 13 (33) 10 (63) 39(34) 10 (63) 26 (35)
No 6 (37) 27 (67) 6 (37) 76 (66) 6 (37) 49 (65)
p = 0.039 p = 0.027 p = 0.039 (chi-2)
Recurrence
Without 12 (75) 31 (77) 12 (75) 54 (69) 12 (75) 85 (74)
With 4 (25) 9 (23) 4 (25) 21 (31) 4 (25) 30 (26)
p = 0.841 p = 0.807 p = 0.926 (chi-2)
* Capsule of the tumor is perforated before or at primary surgery.
Table 5 Predictive factors for positivity of Napsin A
(logistic regression analysis)
Variable OR 95% C.I. P value
Age 0.974 0.917–1.036 0.410
Stage (I vs II) 3.197 0.276–37.054 0.347
Grade 0.942 0.089–9.913 0.962
Clear cell* 152.661 21.042–1107.543 p<0.001
Variable OR 95% C.I. P value
Age 0.998 0.953–1.045 0.941
Stage (I vs II) 0.640 0.120–3.392 0.597
Grade 4.071 0.473–35.038 0.196
P21+p53-** 5.362 1.645–17.476 0.005
Grade# (G1 vs G2 + G3).
Clear cell* (Clear cell vs Type I and Type II tumors in one group (serous,
mucinous, endometrioid and anaplastic)).
p21+p53-** (p21+p53-) vs (p21+p53+, p21-p53+, p21-p53-).
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group
The mean age of patients with clear cell carcinomas
did not significantly differ from that in Type I and II
in one group. No differences were found according to
BMI in two groups, FIGO sub-stages or recurrent
disease between the two groups of patients with clear
cell tumors and patients belonging to Type I and II
in one group. However, capsular rupture occurred
more frequently (p = 0.039) in the group of patients
with clear cell carcinomas. In survival analysis, dis-
ease free survival was not different (Log-rank =
32.977; p = 0.835) between the two subgroups of
patients.
Clear cell tumors could be considered biologically
different from other histological subtypes of epithelial
ovarian cancer. Thus, differences in the immunohis-
tochemical profil for Napsin A and the apoptosis
regulators p21, p53 and concomitant p21 and p53
between the groups of clear cell carcinomas and
other histological subtypes of tumors in one group
(Type I and Type II) could be detected in the
present study.Multivariate analysis
In multivariate logistic regression analysis (Table 5) with
positivity of Napsin A in ovarian tumors as endpoint,
clear cell tumors was the only independent predictive
factor (OR = 153, 95% C.I. 21–1107, p < 0.001) in analysis
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grade (G1/G2 +G3). The variables “clear cell tumors” and
“p21 + p53- status” was not introduced together in the
multivariate models because of a strong correlation
(p < 0.001) between them. In a separate multivariate
analysis (together with the same variables as before)
(Table 5) the p21 + p53- status versus other combina-
tions of p21p53 status in one group was an independ-
ent predictive factor (OR 5.36, 95% C.I. 1.65-17.48,
p = 0.005).
The predictive value of the markers Napsin A, p21 +
p53- and p21 + p53-Napsin A +were evaluated by ROC
curves. As demonstrated in Figure 2 the AUC for Napsin
A alone was 0.882 and in Figure 3 the AUC for p21 +
p53- was 0.720. However, as shown in Figure 4, the AUC
for concomitant p21 + p53- and Napsin A+ decreased to
0.795 compared with the AUC for Napsin A alone.
Discussion
In the present study it was confirmed that ovarian clear
cell carcinomas exhibit clinico-pathological and immuno-
histochemical features that is different from classical Type
I and Type II tumors. The immunohistochemical profil
based on staining for Napsin A and the apoptosis regula-
tors p21, p53 and concomitant p21 and p53 were unique
in the group of clear cell carcinomas compared to other
histological subtypes of tumors (Type I and Type II).Figure 2 ROC curve for “Napsin A phenotype”.Our findings related to the clinico-pathological differ-
ences are supported by earlier studies [4,7,10] but results
about the immunohistochemical profile for Napsin A
is new.
Clear cell carcinomas resembles Type I tumors based
on relative genetic stability and frequent presentation in
stage I, but on the other hand, clear cell carcinoma is
high grade at diagnosis. Furthermore, wild-type p53 is
mostly present and mutations are uncommon in clear
cell tumors contrary to Type II tumors, which are genet-
ically unstable and have a high frequency of p53 muta-
tions [10,11]. Ovarian clear cell carcinomas constitute a
heterogeneous disease at the genomic level despite
having similar histological features. Previous data from
Tan et al. [11] has suggested that the pattern of genome-
wide copy number aberrations may predict clinical
outcome.
Based on our results positivity for Napsin A seems to
be more frequently detected in clear cell carcinomas
than in other histological subtypes. The results are novel
but in agreement with results from Kandalaft et al. [26]
who has shown that Napsin A is highly expressed in 12
out of 12 (100%) ovarian clear cell tumors. We show
further that concomitant positivity for p21 and nega-
tivity for p53 was strongly associated to positive stain-
ing for Napsin A and clear cell tumors, respectively
in the present study. Some difficulties may arise in
Figure 3 ROC curve for “p21 + p53- phenotype”.
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and high grade serous or endometrioid ovarian carcin-
omas [10]. Therefore, concomitant positivity for p21 and
negativity for p53 of a Napsin A positive ovarian tumor
might strengthen the pathological diagnosis of clear cell
ovarian carcinoma. Thus, our findings may facilitate the
morphological diagnosis of clear cell ovarian carcinoma
when there are difficulties in the pathological distinction
between clear cell carcinomas and high grade serous or
endometrioid ovarian carcinomas [10].
No single marker has been reported to be useful alone
to distinguish between high grade serous and clear cell
ovarian carcinoma. In a newly presented study where
seven different markers for distinction between high
grade serous and clear cell ovarian carcinoma did
though p53 in combination with p21 (and Cyclin E, ER,
HNF-1b, WT1 and Ki-67) correctly classify 84% of
tumors with high grade serous compared with clear cell
ovarian carcinoma [27]. Furthermore, as p53 missense
mutations and consequent overexpression (positivity) is
infrequent in clear cell carcinomas, but common in
high-grade serous carcinoma, positive staining for p53
could be a potential marker to distinguish between these
two tumors [27]. In the present study none of the 16
clear cell carcinoma showed positive p53 staining and
our findings are in agreement with others [28,29].Differences in the immunohistochemical profile for
Napsin A and the apoptosis regulators p21, p53 and
concomitant p21 and p53 between the groups of clear
cell carcinomas and other histological subtypes of tu-
mors in one group (Type I and Type II) were detected
in the present study, whereas differences in the p27
status were limited to comparison between clear cell
tumors and Type I tumors.
Findings from ROC curves in the present study
showed that the markers Napsin A, p21 + p53- or p21 +
p53-Napsin A + all had predictive values which might
indicate that they are potential diagnostic markers in the
process of differential diagnosis between clear cell
ovarian carcinomas and other histological subtypes.
However, we found that the p21 + p53- phenotype did
not add to the Napsin A phenotype along the process of
differential diagnosis between clear cell ovarian tumors
and histological subtypes.
In a study on ovarian A2780 cells, it was demonstrated
that p27 up-regulation is linked directly to activation of
the p21/p53 pathway by a DNA-damaging agent (a cis-
platin analogue). Therefore, the p53/p21/p27 axis should
become a new focus of attention in checkpoint response
to DNA damage [30].
In the clinics it is not always obvious how to handle
women with suspected clear cells carcinoma, which
Figure 4 ROC curve for concomitant “p21 + p53-Napsin A + phenotype.
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cancer is usually treated by surgery followed by chemo-
therapy. Though in the group of women diagnosed with
clear cells carcinoma defined by commonly used histo-
pathology a platinum resistance often occurs [6]. Based
on the results described in this study we propose that
Napsin A could not only be used as a diagnostic marker
of clear cells carcinoma, but also might Napsin A
positivity of clear cell carcinoma predict about platinum
sensitivity. Out of there the detection of Napsin A in
clear cell carcinoma could help us to understand how it
promotes resistance to cisplatin by degradation of the
tumor suppressor p53 [12,14].
Similarities between clear cell carcinomas and Type I
tumors, Type II tumors and Type I and Type II tumors
in one group, respectively were limited to FIGO-stages
and recurrent disease.
Patients with clear cell carcinomas were younger than
the Type II tumor patients (55 vs. 60 years; mean age).
In SEER data reported by Chan et al. [6], women with
clear cell histology were younger than patients with
serous cancers. The fraction of patients with BMI > 25
was significantly lower in women with clear cell carcin-
oma compared to woman with type I tumors. This is in
line with previous studies that have reported an elevatedrisk for epithelial ovarian cancer in woman with higher
BMI [31]. This risk seams to be limited to the
histological subgroups of low-grade serous and low to
intermediate grade endometroid [32].
In our material, clear cell carcinomas showed a
significantly higher frequency of capsular rupture
compared to type I tumors, Type II tumors and Type
I/type II combined. Even these results are in line with
earlier findings and likely to contribute to poor prog-
nosis for clear cell carcinomas. In one study improve-
ment was observed in the 5-year disease-free survival
for patients in FIGO-stage I without tumor rupture
during surgery [33]. Rupture (before and during sur-
gery) was the second most powerful prognostic
indicator of disease-free survival (after the degree of
differentiation) in a multicenter study including 1545
patients with invasive epithelial ovarian cancer all in
FIGO-stage I [34].
In the present study the 5-year-survival was not
different for the subgroups of patients with clear cell
ovarian carcinoma from survival for patients with
Type I tumors, Type II tumors or Type I and II in
one group. A number of studies [35] have reported
that overall survival of women with clear cell ovarian
carcinoma is higher than in high grade serous cancer
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survival was worse among women with clear cell
ovarian carcinoma in the high stages (FIGO III-IV).
However, in one of the largest series to date including
1411 clear cell patients comparing 5-year disease-
specific survival rate after adjusting for stage there
was a significantly worse survival rate associated with
clear cell histology compared with other histological
subtypes [6].
NAPA was identified as one of nine cisplatin resist-
ance genes in a genome-wide analysis of HeLa cells
by using DNA microarrays [12]. The chemothera-
peutic agent cisplatin is known to induce apoptosis in
actively replicating cells. Mouse studies and clinical
evidence suggest that wild p53 is required for efficient
apoptosis in tumor cells indicating that intact p53
represents a critical target of chemotherapeutic drugs
[36,37].
Epithelial- mesenchymal transition (EMT) is a multi-
step process, by which polarized epithelial cells lose
epithelial adherence and become capable of free move-
ment through the extracellular matrix. This process is
often activated during cancer invasion and metastasis
[38]. Recently, it has become clear that mutant p53
proteins after losing their transcriptional function can
acquire new functions and drive cell migration, invasion
and metastasis [39]. It was reported from one study [40]
that wild type p53 can inhibit the focal adhesion kinase
(FAK) promoter activity in vitro, but FAK is a critical
regulator of adhesion, motility, metastasis and survival
signalling. Cells without Napsin A appear susceptible to
transition and one of the reasons might be low-level
expression of Napsin A. In a further study [38] it was
demonstrated in an in vitro EMT model that, Napsin A
caused G(0)/(G1) arrest and inhibited the expression of
FAK. Recent reports [7] involving large institutional co-
horts compared low-stage to high-stage ovarian cancers
(I/II vs. III/IV) showed that 57–81% of clear cell carcin-
oma were diagnosed at stage I/II. One reason of the low
frequency of high-stage disease in clear cell ovarian
cancer could theoretically be explained by the findings
from our study of high frequency of Napsin A positivity
and p53 negativity (intact wild type p53) which both
might inhibit the process of EMT in clear cell
carcinoma.
It has been suggested that Napsin A may have a thera-
peutic potential as a gene therapy candidate for tumor
metastasis as increase in expression of Napsin A and
may inhibit the epithelial- mesenchymal transition [41].
In the future the development of high-throughput gene
expression and genomic microarray- based analytical
platforms may answer many important questions about
clear cell ovarian carcinomas [10]. Firstly, if clear cell
ovarian carcinomas are more closely related in molecularterms to other clear cell tumors as renal cell carcin-
omas or endometriod clear cell carcinomas? Does the
potential exist for crossover therapeutic targets to be
developed for clear cell tumors from a variety of
tissue type? Therapy by using the gene NAPA and
the protein, Napsin A could be one option of many
for treatment of clear cell ovarian tumors from of a
variety of tissues in the future.
Some limitations of this work have to be noted. One
limitation corresponds to the relative limited number of
patients included in the study, which though is con-
ducted in a geographically well defined region in
Sweden. However, the frequency of 16 (12.2%) patients
with clear cell ovarian carcinoma out 131 consecutive
patients all with low-stages epithelial ovarian cancer is in
line with the frequency (12.4%) in a previous study in
the same region [28]. Furthermore, the non-serous
(mucinous, endometrioid and clear cell) subtypes usually
are detected in FIGO-stages I-II and therefore repre-
sent uncommon diseases which require large scale re-
search trials for searching for subtype specific
biomarkers [8]. Another limitation is related to the
tissue microarray technology used in this study might
also contribute to some limitations of the work. Only
two 0.6 mm core biopsies were obtained from each
specimen for analysis and there could be a risk of
non- representative tissue collected for microarray. As
ovarian carcinomas can be very heterogeneous, such
specimens may not be representative of the tumor in
some cases. Out of there, we used the method of
semi-quantitative analysis [22] for the interpretation.
Thus, all markers were dichotomized into negative
and positive groups [23]. However, in recent years, it
has been common practice to perform immunohisto-
chemical studies on tissue microarray, where a large
number of antibodies can been screened in a rapid
and cost efficient manner [18].
Conclusions
Differences in the immunohistochemical profil for
Napsin A and the apoptosis regulators p21, p53 and
concomitant p21 and p53 between the groups of clear
cell carcinomas and other histological subtypes of
tumors in one group (Type I and Type II) were found in
the present study, whereas differences in the p27 status
were limited to comparison between clear cell tumors
and Type I tumors. According to the ROC curves we
found that the markers Napsin A, p21 + p53- and p21 +
p53-Napsin A + all had some predictive value as diag-
nostic markers for clear cell ovarian carcinoma. How-
ever, the p21 + p53- phenotype did not add to the
Napsin A phenotype alone along the process of differen-
tial diagnosis between clear cell ovarian tumors and
histological subtypes.
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